Shinhan, Yuanta and Eugene Investment & Securities released reports on Nov. 11 on Hecto Innovation's 2026 third-quarter results. They highlighted growth potential and forecast that profitability improvement would continue.

Hecto Innovation's consolidated third-quarter results for 2026 were revenue of 108.83 billion won and operating profit of 15.26 billion won. That was up 13.8 percent and 4.0 percent from a year earlier, and up 5.8 percent and 18.5 percent from the previous quarter. On a separate basis, third-quarter revenue was 35.07 billion won and operating profit was 9.01 billion won, up 14.9 percent and 20.2 percent year on year.

Eugene Investment & Securities analyst Jong-sun Park (박종선) assessed the third-quarter results by saying revenue posted double-digit year-on-year growth for eight consecutive quarters. He said the company confirmed high and stable sales growth as it achieved revenue in excess of 100 billion won for three consecutive quarters.

Shinhan Investment Corp senior analyst Yu-min Kim (김유민) and research fellow Seung-hwan Choi (최승환) said profit improvement was clearer than top-line growth and described it as confirmation of earnings resilience. Yuanta Securities analyst Myung-jun Kwon (권명준) also said the company posted its biggest quarterly operating profit and said it set record quarterly revenue for six consecutive quarters.

Subsidiary performance also received positive assessments. Yuanta Securities said third-quarter revenue in the fintech business segment, Hecto Financial, was 46.2 billion won, up 15.5 percent year on year. It analyzed the growth as stemming from the expansion of merchants and membership services, which drove simultaneous growth in PG services and simple cash payment revenue.

The healthcare business, Hecto Healthcare, is maintaining quarterly revenue of more than 20.0 billion won. It said the product portfolio is expanding with items such as premium new product DeSIMONE Capsule Premium, which is receiving a positive response, as well as DeSIMONE Pet and Only Ritual.

On the outlook, Yuanta Securities said it expects strong performance even after the fourth quarter. It forecast continued expansion of new services and customer groups on a separate basis. It said a portfolio shift toward high-profit information services is under way, and expects that profitability improvement will accompany it.

It added that the healthcare business is expected to see revenue growth through the launch of related new products in 2027 and an expanded push into overseas markets, following the acquisition of individual functional approval for a function described as "may help reduce body fat."

Eugene Investment & Securities also forecast that the fourth quarter, a peak season, would set a new record for quarterly revenue and enable stable growth. Shinhan Investment Corp also expected profit growth to accelerate again in 2027.

On corporate value, Yuanta Securities assessed that valuation appeal has increased due to a recent share price decline despite improved results. It analyzed that if the third and fourth quarters post the same results, Hecto Innovation's price-to-earnings ratio based on 2026 annual results would be 3.7 times.

Eugene Investment & Securities assessed that the company has shareholder-friendly policies and valuation appeal, alongside expectations of record annual revenue and operating profit.